RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $66 to $62.
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $66 to $62.